1 citations,
January 2015 in “Journal of Aesthetic & Reconstructive Surgery”
Hair transplantation is the best treatment for hair loss, with new technologies improving results, and stem cell and gene therapies may treat severe baldness in the future.
PP405 is a promising molecule that may reactivate dormanthairfollicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Hairfollicles usually go dormant rather than die, and treatments like finasteride, minoxidil, and hormone therapy can sometimes reactivate them, though results vary. Complete regrowth is rare, especially in long-term bald areas, but some individuals see significant improvement with these treatments.
Exosome injections stimulate hair growth by using exosomes' healing potential to awaken dormanthairfollicles and promote new hair cell creation. The procedure increases scalp blood circulation, encourages collagen and elastin formation, and regenerates hairfollicles, improving hair thickness and quality.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hairfollicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
PP405 is not a cure for hair loss but may reactivate dormanthairfollicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.